ClinicalTrials.gg
CompletedNCT02491892Updated Aug 25, 2015Results posted

A Study of Pertuzumab in Participants With Metastatic Breast Cancer

A Phase 2 interventional study of Pertuzumab in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 18 sites in 8 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-25.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.

Enrollment
64th of 104
79 · median 100
Started
2003
the only one that year
Phase 2
59 of 104
17 open now
Registered
36th of 104
by date
Lead sponsor
20 of 104
Hoffmann-La Roche

Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 64th largest by enrollment, is the only one that started in 2003, is one of 59 in phase 2, and was the 36th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 26 open studies →

About pertuzumab

pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing pertuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of pertuzumab (rhuMAb 2C4) in participants with metastatic breast cancer which has progressed during or after standard chemotherapy and which is not amenable to curative therapy. Those who are maintaining a response to therapy or who have stable disease at the end of the formal study period will continue treatment until disease progression or unacceptable toxicity. Approximately 120 participants will be enrolled.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females at least 18 years of age
  • -confirmed breast cancer with low expression and at least one according to (RECIST)
  • performance status at least 80%
  • Disease progression on/after up to 2 different chemotherapy regimens, including an anthracycline-containing therapy
  • (LVEF) at least 50%
  • Adequate liver function

Exclusion criteria

Exclusion Criteria:

  • Pleural effusions, ascites, or bone lesions as the only manifestation(s) of cancer
  • Pulmonary or central nervous system (CNS)
  • Chemotherapy, radiotherapy, or immunotherapy within 4 weeks; or hormone therapy within 2 weeks of Day 1
  • Previous treatment with any drug that targets the receptor family
  • Previous treatment with as cancer therapy
  • History of significant cardiac disease
  • Major surgery or trauma within 4 weeks of Day 1
  • Pregnant or lactating women
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    Pertuzumab 1050 mg

    Participants will not receive a loading dose, but will receive pertuzumab 1050 milligrams (mg) via intravenous (IV) infusion every 3 weeks until unacceptable toxicity or disease progression.

    Drug: Pertuzumab

  • Experimental
    Pertuzumab 420 mg

    Participants will receive a loading dose of 840 mg via IV infusion at the first infusion of pertuzumab, followed by a maintenance dose of 420 mg every 3 weeks until unacceptable toxicity or disease progression.

    Drug: Pertuzumab

Interventions

  • Participants will receive one of two IV treatment regimens with pertuzumab: either 420 mg every 3 weeks, with an initial 840-mg loading dose, or 1050 mg every 3 weeks with no loading dose administered.

    Also known as: rhuMAb 2C4

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR)

    Objective tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed CR was defined as the disappearance of all target lesions, and confirmed PR was defined as at least at 30 percent (%) decrease in the sum of the longest diameters of target lesions. Response was to be confirmed at follow-up assessment completed within 4 weeks of the first documented response. The percentage of participants achieving a best overall response of CR or PR was calculated as \[number of participants meeting the above criteria divided by the number analyzed\] multiplied by 100.

    Time frame: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)

Secondary outcomes

  1. Time to Response Among Participants Achieving a Best Overall Response of Confirmed CR or PR

    Objective tumor response was assessed using RECIST. Confirmed CR was defined as the disappearance of all target lesions, and confirmed PR was defined as at least at 30% decrease in the sum of the longest diameters of target lesions. Response was to be confirmed at follow-up assessment completed within 4 weeks of the first documented response. Time to response was defined as the time from treatment start to first documented response (ie, CR or PR). Participants with stable disease (SD) were censored from the last tumor assessment, and those with progressive disease (PD) or death were assigned an artificial censoring time of 1000 days. Time to response was estimated using Kaplan-Meier and expressed in weeks.

    Time frame: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)

  2. Duration of Response Among Participants Achieving a Best Overall Response of Confirmed CR or PR

    Objective tumor response was assessed using RECIST. Confirmed CR was defined as the disappearance of all target lesions, and confirmed PR was defined as at least at 30% decrease in the sum of the longest diameters of target lesions. Response was to be confirmed at follow-up assessment completed within 4 weeks of the first documented response. Duration of response was defined as the time from first documented response (ie, CR or PR) to PD or death. Participants who did not experience PD or death were censored from the last tumor assessment. Duration of response was estimated using Kaplan-Meier and expressed in weeks.

    Time frame: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)

  3. Percentage of Participants Achieving a Best Overall Response of Confirmed CR

    Objective tumor response was assessed using RECIST. Confirmed CR was defined as the disappearance of all target lesions. Response was to be confirmed at follow-up assessment completed within 4 weeks of the first documented response. The percentage of participants achieving a best overall response of CR was calculated as \[number of participants meeting the above criteria divided by the number analyzed\] multiplied by 100.

    Time frame: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)

  4. Duration of Response Among Participants Achieving a Best Overall Response of Confirmed CR

    Objective tumor response was assessed using RECIST. Confirmed CR was defined as the disappearance of all target lesions. Response was to be confirmed at follow-up assessment completed within 4 weeks of the first documented response. Duration of response was defined as the time from first documented response (ie, CR) to PD or death. Participants who did not experience PD or death were to be censored from the last tumor assessment. Duration of response was to be estimated using Kaplan-Meier.

    Time frame: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)

  5. Number of Participants Who Experienced PD or Death

    Objective tumor response was assessed using RECIST. PD was defined as the appearance of new lesion(s) or at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum obtained at Screening or during treatment. Participants who withdrew from the study early for insufficient therapeutic response without tumor assessment for PD were also included within the definition of PD.

    Time frame: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)

  6. Time to Progression

    Objective tumor response was assessed using RECIST. PD was defined as the appearance of new lesion(s) or at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum obtained at Screening or during treatment. Participants who withdrew from the study early for insufficient therapeutic response without tumor assessment for PD were also included within the definition of PD. Time to progression was defined as the time from treatment start to PD or death. Participants who did not experience PD or death were censored from the last tumor assessment. Time to progression was estimated using Kaplan-Meier and expressed in weeks.

    Time frame: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)

  7. Number of Participants Who Experienced PD or Withdrew From the Study Early

    Objective tumor response was assessed using RECIST. PD was defined as the appearance of new lesion(s) or at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum obtained at Screening or during treatment.

    Time frame: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)

  8. Time to Treatment Failure

    Objective tumor response was assessed using RECIST. PD was defined as the appearance of new lesion(s) or at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum obtained at Screening or during treatment. Time to treatment failure was defined as the time from treatment start to PD or early withdrawal from the study for death, toxicity, refusal/noncompliance, insufficient therapeutic response, or failure to return. Participants who did not experience PD or who did not withdraw from the study early were censored from the last tumor assessment. Time to treatment failure was estimated using Kaplan-Meier and expressed in weeks.

    Time frame: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)

  9. Percentage of Participants Who Died

    The percentage of participants who died was calculated as \[number of participants with event divided by the number analyzed\] multiplied by 100.

    Time frame: Up to approximately 2 years (from start of treatment until death)

  10. Overall Survival

    Overall survival was defined as the time from treatment start to death. Participants who did not die during follow-up were to be censored from the last known alive date. Overall survival was to be estimated using Kaplan-Meier.

    Time frame: Up to approximately 2 years (from start of treatment until death)

  11. Percentage of Participants Achieving a Best Overall Response of SD

    Objective tumor response was assessed using RECIST. SD was defined as neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for PD. The percentage of participants achieving a best overall response of SD was calculated as \[number of participants meeting the above criteria divided by the number analyzed\] multiplied by 100.

    Time frame: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)

  12. Apparent Half-Life (t1/2) of Pertuzumab

    Serum samples were obtained for pharmacokinetic (PK) assessment using a receptor-binding, enzyme-linked immunosorbent assay (ELISA). Pertuzumab concentrations at each collection point were used to determine the apparent t1/2 by non-compartmental analysis, defined as the time elapsed for pertuzumab concentrations to decrease by 50%. The derived value was averaged among all participants and expressed in days.

    Time frame: Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2

  13. Maximum Plasma Concentration (Cmax) of Pertuzumab

    Serum samples were obtained for PK assessment using a receptor-binding ELISA. The maximum observed pertuzumab concentration across all collection points was documented. Cmax was averaged among all participants and expressed in micrograms per milliliter (mcg/mL).

    Time frame: Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2

  14. Time to Maximum Plasma Concentration (Tmax) of Pertuzumab

    Serum samples were obtained for PK assessment using a receptor-binding ELISA. The time of maximum observed pertuzumab concentration across all collection points was documented. Tmax was averaged among all participants and expressed in days.

    Time frame: Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2

  15. Area Under the Concentration-Time Curve (AUC) of Pertuzumab

    Serum samples were obtained for PK assessment using a receptor-binding ELISA. Pertuzumab concentrations at each collection point were used to determine AUC to the last measurable observation (AUClast) and AUC extrapolated to infinity (AUCinf) by non-compartmental analysis. The derived values were averaged among all participants and expressed in days by micrograms per milliliter (days\*mcg/mL).

    Time frame: Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2

  16. Systemic Clearance (CL) of Pertuzumab

    Serum samples were obtained for PK assessment using a receptor-binding ELISA. Pertuzumab concentrations at each collection point were used to determine CL by non-compartmental analysis, defined as the rate at which pertuzumab was removed from the body. The derived value was averaged among all participants and expressed in milliliters per day (mL/day).

    Time frame: Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2

  17. Volume of Distribution at Steady State (Vss) of Pertuzumab

    Serum samples were obtained for PK assessment using a receptor-binding ELISA. Pertuzumab concentrations at each collection point were used to determine the Vss by non-compartmental analysis, defined as the theoretical volume at which the total amount of pertuzumab would be uniformly distributed to produce the desired concentration. The derived value was averaged among all participants and expressed in milliliters (mL).

    Time frame: Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2

  18. Mean Residence Time (MRT) of Pertuzumab

    Serum samples were obtained for PK assessment using a receptor-binding ELISA. Pertuzumab concentrations at each collection point were used to determine the MRT by non-compartmental analysis. The derived value was averaged among all participants and expressed in days.

    Time frame: Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2

  19. Number of Participants Experiencing a Drop in Left Ventricular Ejection Fraction (LVEF) to a Value of Less Than 50%

    Echocardiography was performed to determine LVEF, defined as the volume of blood pumped from the left ventricle as a percentage of end-diastolic volume. Theoretically, LVEF may range from 0 to 100%. The number of participants experiencing a drop in LVEF greater than or equal to (≥) 10 or 15 percentage points to a final LVEF of less than (\<) 50% is reported here.

    Time frame: Up to approximately 1 year (at Baseline; at the end of Cycles 2, 4, 8, 12, and 16; and up to 7 weeks following the last infusion)

07

Results

Posted Aug 25, 2015
Limitations and caveats
Recruitment was halted within the planned study design. The study was designed to stop recruitment following the interim analysis if the response rate (CR or PR) was \<1 of 23 participants per arm after all participants completed at least 2 cycles.

Participant flow

Participant flow — Overall Study
MilestonePertuzumab 420 mgPertuzumab 1050 mg
Started4138
Treated4137
Completed00
Not completed4138
Withdrew: Adverse event11
Withdrew: Death11
Withdrew: Lack of efficacy3736
Withdrew: Refused treatment10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryPercentage of Participants Achieving a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR)

Objective tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed CR was defined as the disappearance of all target lesions, and confirmed PR was defined as at least at 30 percent (%) decrease in the sum of the longest diameters of target lesions. Response was to be confirmed at follow-up assessment completed within 4 weeks of the first documented response. The percentage of participants achieving a best overall response of CR or PR was calculated as \[number of participants meeting the above criteria divided by the number analyzed\] multiplied by 100.

Time frame:
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR)
percentage of participantsPertuzumab 420 mgPertuzumab 1050 mg
Percentage of Participants Achieving a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR)4.90
SecondaryTime to Response Among Participants Achieving a Best Overall Response of Confirmed CR or PR

Objective tumor response was assessed using RECIST. Confirmed CR was defined as the disappearance of all target lesions, and confirmed PR was defined as at least at 30% decrease in the sum of the longest diameters of target lesions. Response was to be confirmed at follow-up assessment completed within 4 weeks of the first documented response. Time to response was defined as the time from treatment start to first documented response (ie, CR or PR). Participants with stable disease (SD) were censored from the last tumor assessment, and those with progressive disease (PD) or death were assigned an artificial censoring time of 1000 days. Time to response was estimated using Kaplan-Meier and expressed in weeks.

Time frame:
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
Reported as:
Median · weeks
Time to Response Among Participants Achieving a Best Overall Response of Confirmed CR or PR
weeksPertuzumab 420 mgPertuzumab 1050 mg
Time to Response Among Participants Achieving a Best Overall Response of Confirmed CR or PR12.1 (6.1 to 18.0)NA (NA to NA)
SecondaryDuration of Response Among Participants Achieving a Best Overall Response of Confirmed CR or PR

Objective tumor response was assessed using RECIST. Confirmed CR was defined as the disappearance of all target lesions, and confirmed PR was defined as at least at 30% decrease in the sum of the longest diameters of target lesions. Response was to be confirmed at follow-up assessment completed within 4 weeks of the first documented response. Duration of response was defined as the time from first documented response (ie, CR or PR) to PD or death. Participants who did not experience PD or death were censored from the last tumor assessment. Duration of response was estimated using Kaplan-Meier and expressed in weeks.

Time frame:
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
Reported as:
Median · weeks
Duration of Response Among Participants Achieving a Best Overall Response of Confirmed CR or PR
weeksPertuzumab 420 mgPertuzumab 1050 mg
Duration of Response Among Participants Achieving a Best Overall Response of Confirmed CR or PR24.6 (18.1 to 31.0)NA (NA to NA)
SecondaryPercentage of Participants Achieving a Best Overall Response of Confirmed CR

Objective tumor response was assessed using RECIST. Confirmed CR was defined as the disappearance of all target lesions. Response was to be confirmed at follow-up assessment completed within 4 weeks of the first documented response. The percentage of participants achieving a best overall response of CR was calculated as \[number of participants meeting the above criteria divided by the number analyzed\] multiplied by 100.

Time frame:
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Best Overall Response of Confirmed CR
percentage of participantsPertuzumab 420 mgPertuzumab 1050 mg
Percentage of Participants Achieving a Best Overall Response of Confirmed CR00
SecondaryDuration of Response Among Participants Achieving a Best Overall Response of Confirmed CR

Objective tumor response was assessed using RECIST. Confirmed CR was defined as the disappearance of all target lesions. Response was to be confirmed at follow-up assessment completed within 4 weeks of the first documented response. Duration of response was defined as the time from first documented response (ie, CR) to PD or death. Participants who did not experience PD or death were to be censored from the last tumor assessment. Duration of response was to be estimated using Kaplan-Meier.

Time frame:
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
Reported as:
Median · weeks
Duration of Response Among Participants Achieving a Best Overall Response of Confirmed CR
weeksPertuzumab 420 mgPertuzumab 1050 mg
Duration of Response Among Participants Achieving a Best Overall Response of Confirmed CRNA (NA to NA)NA (NA to NA)
SecondaryNumber of Participants Who Experienced PD or Death

Objective tumor response was assessed using RECIST. PD was defined as the appearance of new lesion(s) or at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum obtained at Screening or during treatment. Participants who withdrew from the study early for insufficient therapeutic response without tumor assessment for PD were also included within the definition of PD.

Time frame:
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
Reported as:
Number · participants
Number of Participants Who Experienced PD or Death
participantsPertuzumab 420 mgPertuzumab 1050 mg
Number of Participants Who Experienced PD or Death3836
SecondaryTime to Progression

Objective tumor response was assessed using RECIST. PD was defined as the appearance of new lesion(s) or at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum obtained at Screening or during treatment. Participants who withdrew from the study early for insufficient therapeutic response without tumor assessment for PD were also included within the definition of PD. Time to progression was defined as the time from treatment start to PD or death. Participants who did not experience PD or death were censored from the last tumor assessment. Time to progression was estimated using Kaplan-Meier and expressed in weeks.

Time frame:
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
Reported as:
Median · weeks
Time to Progression
weeksPertuzumab 420 mgPertuzumab 1050 mg
Time to Progression6.1 (2.0 to 37.0)6.1 (2.7 to 36.3)
SecondaryNumber of Participants Who Experienced PD or Withdrew From the Study Early

Objective tumor response was assessed using RECIST. PD was defined as the appearance of new lesion(s) or at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum obtained at Screening or during treatment.

Time frame:
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
Reported as:
Number · participants
Number of Participants Who Experienced PD or Withdrew From the Study Early
participantsPertuzumab 420 mgPertuzumab 1050 mg
Number of Participants Who Experienced PD or Withdrew From the Study Early4137
SecondaryTime to Treatment Failure

Objective tumor response was assessed using RECIST. PD was defined as the appearance of new lesion(s) or at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum obtained at Screening or during treatment. Time to treatment failure was defined as the time from treatment start to PD or early withdrawal from the study for death, toxicity, refusal/noncompliance, insufficient therapeutic response, or failure to return. Participants who did not experience PD or who did not withdraw from the study early were censored from the last tumor assessment. Time to treatment failure was estimated using Kaplan-Meier and expressed in weeks.

Time frame:
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
Reported as:
Median · weeks
Time to Treatment Failure
weeksPertuzumab 420 mgPertuzumab 1050 mg
Time to Treatment Failure6.3 (2.0 to 80.1)6.0 (2.7 to 36.3)
SecondaryPercentage of Participants Who Died

The percentage of participants who died was calculated as \[number of participants with event divided by the number analyzed\] multiplied by 100.

Time frame:
Up to approximately 2 years (from start of treatment until death)
Reported as:
Number · percentage of participants
Percentage of Participants Who Died
percentage of participantsPertuzumab 420 mgPertuzumab 1050 mg
Percentage of Participants Who Died4632
SecondaryOverall Survival

Overall survival was defined as the time from treatment start to death. Participants who did not die during follow-up were to be censored from the last known alive date. Overall survival was to be estimated using Kaplan-Meier.

Time frame:
Up to approximately 2 years (from start of treatment until death)

No measurements were reported for this outcome.

SecondaryPercentage of Participants Achieving a Best Overall Response of SD

Objective tumor response was assessed using RECIST. SD was defined as neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for PD. The percentage of participants achieving a best overall response of SD was calculated as \[number of participants meeting the above criteria divided by the number analyzed\] multiplied by 100.

Time frame:
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Best Overall Response of SD
percentage of participantsPertuzumab 420 mgPertuzumab 1050 mg
Percentage of Participants Achieving a Best Overall Response of SD43.937.8
SecondaryApparent Half-Life (t1/2) of Pertuzumab

Serum samples were obtained for pharmacokinetic (PK) assessment using a receptor-binding, enzyme-linked immunosorbent assay (ELISA). Pertuzumab concentrations at each collection point were used to determine the apparent t1/2 by non-compartmental analysis, defined as the time elapsed for pertuzumab concentrations to decrease by 50%. The derived value was averaged among all participants and expressed in days.

Time frame:
Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
Reported as:
Mean · days
Apparent Half-Life (t1/2) of Pertuzumab
daysPertuzumab 420 mgPertuzumab 1050 mg
Apparent Half-Life (t1/2) of Pertuzumab12.2 ± 3.911.4 ± 4.1
SecondaryMaximum Plasma Concentration (Cmax) of Pertuzumab

Serum samples were obtained for PK assessment using a receptor-binding ELISA. The maximum observed pertuzumab concentration across all collection points was documented. Cmax was averaged among all participants and expressed in micrograms per milliliter (mcg/mL).

Time frame:
Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
Reported as:
Mean · mcg/mL
Maximum Plasma Concentration (Cmax) of Pertuzumab
mcg/mLPertuzumab 420 mgPertuzumab 1050 mg
Maximum Plasma Concentration (Cmax) of Pertuzumab289 ± 107409 ± 159
SecondaryTime to Maximum Plasma Concentration (Tmax) of Pertuzumab

Serum samples were obtained for PK assessment using a receptor-binding ELISA. The time of maximum observed pertuzumab concentration across all collection points was documented. Tmax was averaged among all participants and expressed in days.

Time frame:
Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
Reported as:
Median · days
Time to Maximum Plasma Concentration (Tmax) of Pertuzumab
daysPertuzumab 420 mgPertuzumab 1050 mg
Time to Maximum Plasma Concentration (Tmax) of Pertuzumab0.073 (0.052 to 7)0.073 (0.059 to 0.122)
SecondaryArea Under the Concentration-Time Curve (AUC) of Pertuzumab

Serum samples were obtained for PK assessment using a receptor-binding ELISA. Pertuzumab concentrations at each collection point were used to determine AUC to the last measurable observation (AUClast) and AUC extrapolated to infinity (AUCinf) by non-compartmental analysis. The derived values were averaged among all participants and expressed in days by micrograms per milliliter (days\*mcg/mL).

Time frame:
Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
Reported as:
Mean · days*mcg/mL
Area Under the Concentration-Time Curve (AUC) of Pertuzumab
days*mcg/mLPertuzumab 420 mgPertuzumab 1050 mg
AUClast (n=40,37)2517 ± 8963465 ± 1051
AUCinf (n=38,36)3598 ± 14024750 ± 1527
SecondarySystemic Clearance (CL) of Pertuzumab

Serum samples were obtained for PK assessment using a receptor-binding ELISA. Pertuzumab concentrations at each collection point were used to determine CL by non-compartmental analysis, defined as the rate at which pertuzumab was removed from the body. The derived value was averaged among all participants and expressed in milliliters per day (mL/day).

Time frame:
Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
Reported as:
Mean · mL/day
Systemic Clearance (CL) of Pertuzumab
mL/dayPertuzumab 420 mgPertuzumab 1050 mg
Systemic Clearance (CL) of Pertuzumab270 ± 113247 ± 90
SecondaryVolume of Distribution at Steady State (Vss) of Pertuzumab

Serum samples were obtained for PK assessment using a receptor-binding ELISA. Pertuzumab concentrations at each collection point were used to determine the Vss by non-compartmental analysis, defined as the theoretical volume at which the total amount of pertuzumab would be uniformly distributed to produce the desired concentration. The derived value was averaged among all participants and expressed in milliliters (mL).

Time frame:
Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
Reported as:
Mean · mL
Volume of Distribution at Steady State (Vss) of Pertuzumab
mLPertuzumab 420 mgPertuzumab 1050 mg
Volume of Distribution at Steady State (Vss) of Pertuzumab4122 ± 16663527 ± 1369
SecondaryMean Residence Time (MRT) of Pertuzumab

Serum samples were obtained for PK assessment using a receptor-binding ELISA. Pertuzumab concentrations at each collection point were used to determine the MRT by non-compartmental analysis. The derived value was averaged among all participants and expressed in days.

Time frame:
Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
Reported as:
Mean · days
Mean Residence Time (MRT) of Pertuzumab
daysPertuzumab 420 mgPertuzumab 1050 mg
Mean Residence Time (MRT) of Pertuzumab16 ± 515 ± 6
SecondaryNumber of Participants Experiencing a Drop in Left Ventricular Ejection Fraction (LVEF) to a Value of Less Than 50%

Echocardiography was performed to determine LVEF, defined as the volume of blood pumped from the left ventricle as a percentage of end-diastolic volume. Theoretically, LVEF may range from 0 to 100%. The number of participants experiencing a drop in LVEF greater than or equal to (≥) 10 or 15 percentage points to a final LVEF of less than (\<) 50% is reported here.

Time frame:
Up to approximately 1 year (at Baseline; at the end of Cycles 2, 4, 8, 12, and 16; and up to 7 weeks following the last infusion)
Reported as:
Number · participants
Number of Participants Experiencing a Drop in Left Ventricular Ejection Fraction (LVEF) to a Value of Less Than 50%
participantsPertuzumab 420 mgPertuzumab 1050 mg
Drop ≥10 percentage points35
Drop ≥15 percentage points33

Adverse events

Collected over Up to approximately 1 year (from start of treatment until up to 7 weeks following the last infusion). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pertuzumab 420 mg—10/41 (24.4%)36/41 (87.8%)
Pertuzumab 1050 mg—8/37 (21.6%)37/37 (100%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPertuzumab 420 mgPertuzumab 1050 mg
Ejection fraction decreasedInvestigations2/410/37
AscitesGastrointestinal disorders1/411/37
DiarrhoeaGastrointestinal disorders0/411/37
DysphagiaGastrointestinal disorders0/411/37
Large intestinal obstructionGastrointestinal disorders0/411/37
Pleural effusionRespiratory, thoracic and mediastinal disorders1/411/37
EpistaxisRespiratory, thoracic and mediastinal disorders0/411/37
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders0/411/37
UrticariaSkin and subcutaneous tissue disorders0/411/37
Lung infectionInfections and infestations1/410/37
Most frequent other events
Showing 10 of 40
Most frequent other events
EventPertuzumab 420 mgPertuzumab 1050 mg
DiarrhoeaGastrointestinal disorders24/4122/37
NauseaGastrointestinal disorders12/4113/37
AstheniaGeneral disorders10/419/37
VomitingGastrointestinal disorders10/418/37
AnorexiaMetabolism and nutrition disorders4/418/37
HeadacheNervous system disorders7/415/37
Abdominal pain upperGastrointestinal disorders6/416/37
RashSkin and subcutaneous tissue disorders6/414/37
DyspnoeaRespiratory, thoracic and mediastinal disorders5/415/37
FatigueGeneral disorders5/415/37

Baseline characteristics

Intent-to-Treat (ITT) Population: All randomized participants who received at least one dose of pertuzumab.

Age, Continuous
Age, Continuous(years)Pertuzumab 420 mgPertuzumab 1050 mgTotal
Mean55.3 ± 10.0453.5 ± 8.7254.4 ± 9.42
Sex: Female, Male
Sex: Female, Male(Participants)Pertuzumab 420 mgPertuzumab 1050 mgTotal
Female413778
Male000
08

Study locations

18 sites
  • Camperdown, 2050, Australia
  • Fitzroy, 3065, Australia
  • Geelong, 3220, Australia
  • Namur, 5000, Belgium
  • Helsinki, 00029, Finland
  • Tampere, 33520, Finland
  • Hamburg, 20246, Germany
  • Herne, 44625, Germany
  • München, 81675, Germany
  • Milano, 20133, Italy
  • Parma, 43100, Italy
  • Amsterdam, 1081 HV, Netherlands
  • Barcelona, 08035, Spain
  • Barcelona, 08907, Spain
  • Valencia, 46009, Spain
  • Edinburgh, EH4 2XU, United Kingdom
  • London, SE1 9RT, United Kingdom
  • Manchester, M20 4BX, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of Apr 2005 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 10 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2015
First posted
Jul 8, 2015
Start
Feb 2003
Primary completionActual
Apr 2005
CompletionActual
Apr 2005
Results first posted
Aug 25, 2015
Last update
Aug 25, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02491892
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 8, 2015
Start date
Feb 2003
Primary completion
Apr 2005
Completion
Apr 2005
Results posted
Aug 25, 2015
Last update
Aug 25, 2015

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pertuzumab

Start the discussion